- Home
- CAH vs MRNA Comparison
CAH vs MRNA Comparison
Compare CAH & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAH | MRNA |
|---|---|---|
| Founded | 1979 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0B | 61.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CAH | MRNA |
|---|---|---|
| Price | $255.78 | $241.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 23 |
| Target Price | ★ $271.47 | $123.61 |
| AVG Volume (30 Days) | 1.4M | ★ 15.0M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | 12.09 | ★ 21.77 |
| EPS | ★ 7.23 | N/A |
| Revenue | ★ $254,248,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $4.53 | $8.09 |
| Revenue Next Year | $6.05 | $16.06 |
| P/E Ratio | $34.63 | ★ N/A |
| Revenue Growth | ★ 14.23 | 4.29 |
| 52 Week Low | $157.79 | $22.28 |
| 52 Week High | $258.30 | $242.29 |
Technical Indicators
Market Signals| Indicator | CAH | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 67.75 | 64.66 |
| Support Level | $216.88 | $45.39 |
| Resistance Level | $258.30 | N/A |
| Average True Range (ATR) | 5.50 | 16.80 |
| MACD | 2.73 | 0.03 |
| Stochastic Oscillator | 84.35 | 70.17 |
Price Performance
Historical ComparisonAbout CAH Cardinal Health Inc.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.